Niklas Mattsson
Reproducibility track record
1
assessed papers
93/100
mean reproducibility
1
reproduced (C1–C2)
0
flagged
724
total citations
flag rate:
0%
(0/1)
The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.
Authorship role
first author: 0
last author: 0
Topics
Funders
—
Frequent co-authors
Anette Kalnapenkis 1Tõnu Esko 1Elise J. Needham 1Mari Nelis 1Barbara Thorand 1Leonid Padyukov 1Michael Roden 1Dirk S. Paul 1Mikael Landén 1Ulf Gyllensten 1
Institutions
University of Cambridge 1University of South Australia 1South Australian Health and Medical Research Institute 1Uppsala University 1University of Edinburgh 1Karolinska Institutet 1
Geography (author institutions)
GB 1AU 1SE 1EE 1DE 1HR 1
Co-author network
Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.
How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.
Assessed papers (1)
Complete publication record (583)
Request a reproduction →1 assessed by us (1 reproduced) · 582 not yet assessed — every PubMed paper on record, linked below.
-
Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology ↗Brain · 2026 · PMID 41562409not yet assessed
-
Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome ↗Cell · 2026 · PMID 42097137not yet assessed
-
Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum ↗Nature Communications · 2026 · PMID 41957377not yet assessed
-
Neuropathological correlates of age and sex differences in 18F-flortaucipir PET ↗Brain · 2026 · PMID 42010343not yet assessed
-
Associations of modifiable and non-modifiable risk factors with longitudinal white matter hyperintensities, amyloid-β and tau - a prospective cohort study ↗The Journal of Prevention of Alzheimer s Disease · 2026 · PMID 41478835not yet assessed
-
Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias ↗Nature Aging · 2026 · PMID 42477094not yet assessed
-
Dynamical A β -Tau-Neurodegeneration Model Predicts Alzheimer’s Disease Mechanisms and Biomarker Progression ↗bioRxiv (Cold Spring Harbor Laboratory) · 2026 · PMID 41659595not yet assessed
-
Brain network dynamics determine tau presence while regional vulnerability governs tau load in Alzheimer’s disease ↗Research Square · 2026 · PMID 41928804not yet assessed
-
Stable episodic memory and high education do not influence the rate of Alzheimer’s disease pathology as measured by plasma p-tau217 ↗bioRxiv (Cold Spring Harbor Laboratory) · 2026 · PMID 42079294not yet assessed
-
Blood and CSF Biomarkers in Amyotrophic Lateral Sclerosis: Diagnostic and Prognostic Insights from a Systematic Review and Meta-analysisLund University Publications (Lund University) · 2026not yet assessed
-
Turning as a single and dual task—associations with Alzheimer’s and vascular pathologies in cognitively healthy older people ↗The Journals of Gerontology Series A · 2026 · PMID 42109046not yet assessed
-
Proximity-extension dementia-panel in 41 brain disorders: a meta-analysis ↗Research Square · 2026not yet assessed
-
Benchmarking privacy and utility in synthetic tabular cohorts for Alzheimer's disease research ↗Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2026 · PMID 42582267not yet assessed
-
CSF p-tau205: a biomarker of Alzheimer’s disease progression and biological staging ↗Molecular Psychiatry · 2026 · PMID 42661061not yet assessed
-
Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease ↗Nature Aging · 2026 · PMID 42141098not yet assessed
-
Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females ↗European Journal of Nuclear Medicine and Molecular Imaging · 2026 · PMID 42191949not yet assessed
-
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform ↗Nature Medicine · 2025 · PMID 40205199not yet assessed
-
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging ↗Nature Medicine · 2025 · PMID 40665048not yet assessed
-
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease ↗Nature Medicine · 2025 · PMID 40164726not yet assessed
-
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials ↗Nature Aging · 2025 · PMID 40155777not yet assessed
-
Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease ↗JAMA Neurology · 2025 · PMID 40388185not yet assessed
-
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease ↗JAMA Neurology · 2025 · PMID 40952756not yet assessed
-
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex ↗Nature Neuroscience · 2025 · PMID 40670684not yet assessed
-
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum ↗Brain · 2025 · PMID 39879633not yet assessed
-
A comparison of p‐tau assays for the specificity to detect tau changes in Alzheimer's disease ↗Alzheimer s & Dementia · 2025 · PMID 40289884not yet assessed
-
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data ↗Alzheimer s & Dementia · 2025 · PMID 39985487not yet assessed
-
Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study ↗Alzheimer s & Dementia · 2025 · PMID 40551285not yet assessed
-
Plasma tau biomarkers for biological staging of Alzheimer’s disease ↗Nature Aging · 2025 · PMID 40847200not yet assessed
-
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-β ↗Brain · 2025 · PMID 39817469not yet assessed
-
Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice ↗Nature Aging · 2025 · PMID 39939821not yet assessed
-
Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease ↗JAMA Neurology · 2025 · PMID 40853684not yet assessed
-
Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers ↗Nature Medicine · 2025 · PMID 40954312not yet assessed
-
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment ↗Nature Communications · 2025 · PMID 39881147not yet assessed
-
Estimating the time course of biomarker changes in Alzheimer’s disease ↗Brain · 2025 · PMID 41178353not yet assessed
-
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study ↗The Lancet Neurology · 2025 · PMID 40541209not yet assessed
-
Diagnostic and Prognostic Value of Blood and Cerebrospinal Fluid Biomarkers in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta‐Analysis ↗European Journal of Neurology · 2025 · PMID 41140053not yet assessed
-
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease ↗Nature Communications · 2025 · PMID 40913038not yet assessed
-
Personalised regional modelling predicts tau progression in the human brain ↗PLoS Biology · 2025 · PMID 40690524not yet assessed
-
Benchmarking Alzheimer’s disease prediction: personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies ↗Alzheimer s Research & Therapy · 2025 · PMID 39762974not yet assessed
-
Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease ↗Alzheimer s & Dementia · 2025 · PMID 40709494not yet assessed
-
Longitudinal tau aggregation, atrophy, and cognitive decline in Alzheimer's disease ↗Alzheimer s & Dementia · 2025 · PMID 40629696not yet assessed
-
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals ↗Alzheimer s & Dementia · 2025 · PMID 40883967not yet assessed
-
Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease ↗Alzheimer s & Dementia · 2025 · PMID 41088853not yet assessed
-
Biological classification of memory clinic patients ↗Brain · 2025 · PMID 41157967not yet assessed
-
Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [18F]flortaucipir imaging: TAU-SPEX ↗European Journal of Nuclear Medicine and Molecular Imaging · 2025 · PMID 40481862not yet assessed
-
Clinical Performance of the Elecsys CSF pTau181/Aβ42 Ratio for Concordance with Tau-PET in Two Independent Cohorts ↗Neurology and Therapy · 2025 · PMID 40684402not yet assessed
-
Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid ↗EMBO Molecular Medicine · 2025 · PMID 41326715not yet assessed
-
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers ↗Brain · 2025 · PMID 41051312not yet assessed
-
Brain network dynamics determine tau presence while regional vulnerability governs tau load in Alzheimer’s disease ↗bioRxiv (Cold Spring Harbor Laboratory) · 2025not yet assessed
-
Benchmarking the AI-based diagnostic potential of plasma proteomics for neurodegenerative disease in 17,187 people ↗medRxiv · 2025 · PMID 40630573not yet assessed
-
Concurrent longitudinal changes in plasma p-tau217, tau PET, and cognition in preclinical Alzheimer’s disease ↗medRxiv · 2025not yet assessed
-
Brain Network Dynamics Determine Tau Presence While Regional Vulnerability Governs Tau Load in Alzheimer's Disease ↗SSRN Electronic Journal · 2025not yet assessed
-
Hemispheric Asymmetry of Tau Pathology is Related to Asymmetric Amyloid Deposition in Alzheimer’s Disease ↗bioRxiv (Cold Spring Harbor Laboratory) · 2025not yet assessed
-
Different functional connectivity gradients reflect aging and Alzheimer’s disease ↗bioRxiv (Cold Spring Harbor Laboratory) · 2025 · PMID 40661536not yet assessed
-
Correction to: Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [18F]flortaucipir imaging: TAU-SPEX ↗European Journal of Nuclear Medicine and Molecular Imaging · 2025 · PMID 40610702not yet assessed
-
Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease ↗medRxiv · 2025 · PMID 40799961not yet assessed
-
Plasma biomarker profiles in ageing: decoding neurodegeneration in vivo ↗Brain · 2025 · PMID 40795087not yet assessed
-
Predictive Value of Plasma Biomarkers in Tau‐ PET Transitions ↗Annals of Neurology · 2025 · PMID 40927954not yet assessed
-
Cell-weighted polygenic risk scores are associated with β-amyloid and tau biomarkers in Alzheimer’s disease ↗Brain Communications · 2025 · PMID 41040848not yet assessed
-
Patient-specific functional brain architecture explains cortical patterns of tau PET in Alzheimer's disease ↗bioRxiv (Cold Spring Harbor Laboratory) · 2025 · PMID 41256509not yet assessed
-
P-TAU205 IS A BIOMARKER LINKED TO TAU-PET ABNORMALITY: A CROSS-SECTIONAL AND LONGITUDINAL STUDY ↗medRxiv · 2025 · PMID 41282659not yet assessed
-
Converting T1-weighted MRI from 3T to 7T quality using deep learning ↗arXiv (Cornell University) · 2025not yet assessed
-
Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests ↗Nature Medicine · 2024 · PMID 38382645not yet assessed
-
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care ↗JAMA · 2024 · PMID 39068545not yet assessed
-
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment ↗JAMA Neurology · 2024 · PMID 39068669not yet assessed
-
Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies ↗Nature Neuroscience · 2024 · PMID 39187705not yet assessed
-
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests ↗Brain · 2024 · PMID 39468767not yet assessed
-
Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability ↗Nature Aging · 2024 · PMID 39533113not yet assessed
-
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment ↗JAMA Neurology · 2024 · PMID 38857029not yet assessed
-
Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases ↗Nature Communications · 2024 · PMID 38693142not yet assessed
-
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease ↗Molecular Neurodegeneration · 2024 · PMID 38365825not yet assessed
-
Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease ↗Nature Communications · 2024 · PMID 39277604not yet assessed
-
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings ↗Brain · 2024 · PMID 38654513not yet assessed
-
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings ↗Nature Communications · 2024 · PMID 38486040not yet assessed
-
Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum ↗Brain · 2024 · PMID 39689039not yet assessed
-
Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo ↗Alzheimer s & Dementia · 2024 · PMID 39258841not yet assessed
-
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study ↗Scientific Reports · 2024 · PMID 39455624not yet assessed
-
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease ↗Alzheimer s Research & Therapy · 2024 · PMID 39285454not yet assessed
-
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology ↗Molecular Neurodegeneration · 2024 · PMID 38185677not yet assessed
-
Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer’s disease ↗Cell Reports Medicine · 2024 · PMID 39293391not yet assessed
-
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns ↗Alzheimer s Research & Therapy · 2024 · PMID 38970077not yet assessed
-
Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest ↗Critical Care · 2024 · PMID 38594704not yet assessed
-
Biological mechanisms of resilience to tau pathology in Alzheimer’s disease ↗Alzheimer s Research & Therapy · 2024 · PMID 39396028not yet assessed
-
MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population ↗JAMA Neurology · 2024 · PMID 39068668not yet assessed
-
Evaluation of the prospective use of blood biomarkers for Alzheimer’s disease in primary and secondary care ↗Alzheimer s & Dementia · 2024not yet assessed
-
Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders ↗Brain Communications · 2024 · PMID 39605973not yet assessed
-
Head‐to‐Head Comparison of Four Plasma Phosphorylated Tau 217 Biomarkers ↗Alzheimer s & Dementia · 2024not yet assessed
-
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms ↗Alzheimer s Research & Therapy · 2024 · PMID 38504336not yet assessed
-
Disentangling genetic risks for development and progression of Alzheimer’s disease ↗Brain · 2024 · PMID 39018494not yet assessed
-
A head‐to‐head comparison between plasma p‐tau217 and tau‐PET for predicting future cognitive decline among cognitively unimpaired individuals ↗Alzheimer s & Dementia · 2024not yet assessed
-
Regional Amyloid Load Predicts Tau and Atrophy Dynamics ↗Alzheimer s & Dementia · 2024not yet assessed
-
A generalizable data‐driven model of atrophy heterogeneity and progression in a memory clinic setting ↗Alzheimer s & Dementia · 2024not yet assessed
-
The prevalence of tau‐PET positivity in aging and dementia ↗Alzheimer s & Dementia · 2024not yet assessed
-
The MRI signature of alpha‐synuclein pathology in preclinical stages and in a memory clinic population ↗Alzheimer s & Dementia · 2024not yet assessed
-
A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests ↗medRxiv · 2024 · PMID 39006421not yet assessed
-
Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology ↗medRxiv · 2024 · PMID 38947004not yet assessed
-
Identification of distinct and shared biomarker panels in different manifestations of cerebral small vessel disease through proteomic profiling ↗medRxiv · 2024 · PMID 38947084not yet assessed
-
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer’s disease ↗bioRxiv (Cold Spring Harbor Laboratory) · 2024 · PMID 38826333not yet assessed
-
A machine learning-based prediction of tau load and distribution in Alzheimer’s disease using plasma, MRI and clinical variables ↗medRxiv · 2024 · PMID 38853877not yet assessed
-
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta ↗medRxiv · 2024not yet assessed
-
Dynamic associations between tau aggregation, atrophy, and cognitive decline in Alzheimer’s disease ↗medRxiv · 2024not yet assessed
-
Plasma Tau Biomarkers for Alzheimer's Disease Staging ↗Alzheimer s & Dementia · 2024not yet assessed
-
Optimizing tau‐PET referrals in memory clinics through a blood biomarker workflow ↗Alzheimer s & Dementia · 2024not yet assessed
-
Individual variation in proteomic cascades along the Alzheimer’s disease spectrum ↗Alzheimer s & Dementia · 2024not yet assessed
-
A generalizable data‐driven model of atrophy heterogeneity and progression in a memory clinic setting ↗Alzheimer s & Dementia · 2024not yet assessed
-
A highly accurate blood test for Alzheimer’s disease pathology has performance equivalent or superior to clinically used CSF tests ↗Alzheimer s & Dementia · 2024not yet assessed
-
A combination of plasma phospho‐tau217 and Aβ42/40 detects early development of amyloid pathology in cognitively unimpaired individuals ↗Alzheimer s & Dementia · 2024not yet assessed
-
Data‐driven progression patterns of Aβ, tau, α‐synuclein and vascular pathology in a clinical population ↗Alzheimer s & Dementia · 2024not yet assessed
-
Proteomics analysis characterizing new markers related to Aβ plaques and tau tangles pathologies ↗Alzheimer s & Dementia · 2024not yet assessed
-
Use of plasma p‐tau217 as a pre‐screening method for detecting amyloid‐PET positivity in cognitively unimpaired participants: A multicenter study ↗Alzheimer s & Dementia · 2024not yet assessed
-
Unlocking Tau PET Accessibility: a Machine Learning‐Based Prediction of Tau Pathology from Plasma, MRI and Clinical Variables ↗Alzheimer s & Dementia · 2024not yet assessed
-
Associations between tau accumulation and cognitive decline across the AD continuum differ by sex ↗Alzheimer s & Dementia · 2024not yet assessed
-
Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease ↗Alzheimer s & Dementia · 2024not yet assessed
-
Associations between tau accumulation and cognitive decline across the AD continuum differ by sex ↗Alzheimer s & Dementia · 2024not yet assessed
-
The prevalence of tau‐PET positivity in aging and dementia ↗Alzheimer s & Dementia · 2024not yet assessed
-
Impact of regional MAPT, APOE, and Aβ on tau propagation in Alzheimer’s disease: Insights from a connectome‐based simulation model ↗Alzheimer s & Dementia · 2024not yet assessed
-
Data‐driven progression patterns of Aβ, tau, α‐synuclein and vascular pathology in a clinical population ↗Alzheimer s & Dementia · 2024not yet assessed
-
Improved precision of Alzheimer’s disease fluid biomarkers when using Amyloid‐β40 or non‐phosphorylated tau as a reference ↗Alzheimer s & Dementia · 2024not yet assessed
-
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targetsNature Immunology · 2023 · PMID 37563310L1 93/100
-
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers ↗JAMA Neurology · 2023 · PMID 36745413not yet assessed
-
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease ↗Nature Medicine · 2023 · PMID 37443334not yet assessed
-
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads ↗EMBO Molecular Medicine · 2023 · PMID 36912178not yet assessed
-
Cognitive effects of Lewy body pathology in clinically unimpaired individuals ↗Nature Medicine · 2023 · PMID 37464059not yet assessed
-
Clinical effects of Lewy body pathology in cognitively impaired individuals ↗Nature Medicine · 2023 · PMID 37464058not yet assessed
-
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies ↗JAMA Neurology · 2023 · PMID 38048096not yet assessed
-
Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease ↗Brain Communications · 2023 · PMID 37013174not yet assessed
-
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease ↗Nature Aging · 2023 · PMID 37723208not yet assessed
-
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia ↗Neurology · 2023 · PMID 36882326not yet assessed
-
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes ↗Neurology · 2023 · PMID 37137722not yet assessed
-
Age-related and amyloid-beta-independent tau deposition and its downstream effects ↗Brain · 2023 · PMID 37082959not yet assessed
-
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi‐cohort study ↗Alzheimer s & Dementia · 2023 · PMID 36648169not yet assessed
-
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease ↗JAMA Neurology · 2023 · PMID 37155176not yet assessed
-
Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes ↗Alzheimer s & Dementia · 2023 · PMID 36681387not yet assessed
-
Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest ↗Critical Care · 2023 · PMID 36829239not yet assessed
-
Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective cohort study ↗Brain Communications · 2023 · PMID 37091584not yet assessed
-
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease ↗Brain Communications · 2023 · PMID 36926368not yet assessed
-
The emerging era of staging Alzheimer’s disease pathology using plasma biomarkers ↗Brain · 2023 · PMID 37019849not yet assessed
-
Direct Conversion of Fibroblast into Neurons for Alzheimer’s Disease Research: A Systematic Review ↗Journal of Alzheimer s Disease · 2023 · PMID 37661882not yet assessed
-
Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease ↗Neurology · 2023 · PMID 37085326not yet assessed
-
Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment ↗Journal of Alzheimer s Disease · 2023 · PMID 37742636not yet assessed
-
Plasma pTau181 and biomarker combinations to identify Alzheimer´s disease at any stage along the AD continuum compared with both controls and non‐AD dementia ↗Alzheimer s & Dementia · 2023not yet assessed
-
Identification of Distinct and Shared Biomarkers in Cerebral Small Vessel Disease (SVD) through Proteomic Profiling of Cerebrospinal Fluid ↗Alzheimer s & Dementia · 2023not yet assessed
-
Optimal combination of CSF phosphorylated‐tau forms to predict Alzheimer’s disease pathological burden as measured by PET ↗Alzheimer s & Dementia · 2023not yet assessed
-
Microtubule‐binding region tau fragment tau368 as a biomarker of Alzheimer’s disease ↗Alzheimer s & Dementia · 2023not yet assessed
-
Tau‐PET to predict conversion from mild cognitive impairment to dementia; a head‐to‐head comparison against amyloid‐PET and MRI ↗Alzheimer s & Dementia · 2023not yet assessed
-
Carbon dioxide flooding to reduce postoperative neurological injury following surgery for acute type A aortic dissection: a prospective, randomised, blinded, controlled clinical trial, CARTA study protocol - objectives and design ↗BMJ Open · 2023 · PMID 37230515not yet assessed
-
Author Correction: Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets ↗Nature Immunology · 2023 · PMID 37679551not yet assessed
-
Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases ↗bioRxiv (Cold Spring Harbor Laboratory) · 2023not yet assessed
-
Personalised Regional Modelling Predicts Tau Progression in the Human Brain ↗bioRxiv (Cold Spring Harbor Laboratory) · 2023not yet assessed
-
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms ↗Research Square · 2023 · PMID 37986841not yet assessed
-
Mapping pQTLs of circulating inflammatory proteins identifies drivers of immune-related disease risk and novel therapeutic targets ↗medRxiv · 2023not yet assessed
-
Associations between placental growth factor, white matter lesions, and vascular risk factors in non‐demented elderly individuals ↗Alzheimer s & Dementia · 2023not yet assessed
-
Biofluid phospho‐tau with subthreshold tau‐PET predicts higher rates of tau accumulation: implications for secondary prevention trials ↗Alzheimer s & Dementia · 2023not yet assessed
-
Targeted proteomic profiling in cerebrospinal fluid and plasma identifies biomarkers for Alzheimer’s disease ↗Alzheimer s & Dementia · 2023not yet assessed
-
Lessons from neuropathology to inform on fluid biomarkers of amyloid and tau ↗Alzheimer s & Dementia · 2023not yet assessed
-
Tau‐PET to predict conversion from mild cognitive impairment to dementia; a head‐to‐head comparison against amyloid‐PET and MRI ↗Alzheimer s & Dementia · 2023not yet assessed
-
Associations between tau‐PET and neurodegeneration with cognitive and behavioural changes over time in amyloid‐positive individuals ↗Alzheimer s & Dementia · 2023not yet assessed
-
What do elevated cerebrospinal fluid p‐tau levels signify in the absence of beta‐amyloid pathology? ↗Alzheimer s & Dementia · 2023not yet assessed
-
Plasma protein profiling reveals novel specific biomarkers reflecting the multifactorial nature of Alzheimer´s disease continuum ↗Alzheimer s & Dementia · 2023not yet assessed
-
Adjusting for CSF Reference Proteins Improves Biomarker Accuracy ↗Alzheimer s & Dementia · 2023not yet assessed
-
Associations between tau‐PET and neurodegeneration with cognitive and behavioural changes over time in amyloid‐positive individuals ↗Alzheimer s & Dementia · 2023not yet assessed
-
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring ↗Nature Medicine · 2022 · PMID 36456833not yet assessed
-
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum ↗JAMA Neurology · 2022 · PMID 35099509not yet assessed
-
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance ↗Alzheimer s & Dementia · 2022 · PMID 36152307not yet assessed
-
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease ↗Alzheimer s & Dementia · 2022 · PMID 35950735not yet assessed
-
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease ↗Nature Communications · 2022 · PMID 36333294not yet assessed
-
Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models ↗Alzheimer s & Dementia · 2022 · PMID 35699240not yet assessed
-
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology ↗Nature Aging · 2022 · PMID 37118533not yet assessed
-
Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline ↗Biological Psychiatry · 2022 · PMID 35346458not yet assessed
-
Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients ↗Alzheimer s & Dementia · 2022 · PMID 36516028not yet assessed
-
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum ↗Molecular Neurodegeneration · 2022 · PMID 36510321not yet assessed
-
The genetic regulation of protein expression in cerebrospinal fluid ↗EMBO Molecular Medicine · 2022 · PMID 36504281not yet assessed
-
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals ↗Brain · 2022 · PMID 36084009not yet assessed
-
Components of gait in people with and without mild cognitive impairment ↗Gait & Posture · 2022 · PMID 35101749not yet assessed
-
Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers ↗Brain Communications · 2022 · PMID 35702728not yet assessed
-
Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest ↗Brain Injury · 2022 · PMID 35253570not yet assessed
-
Brain injury markers in blood predict signs of hypoxic ischaemic encephalopathy on head computed tomography after cardiac arrest ↗Resuscitation · 2022 · PMID 36563954not yet assessed
-
General anesthesia in early childhood and possible association with autism: a population-based matched cohort study ↗Minerva Anestesiologica · 2022 · PMID 36282219not yet assessed
-
Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitizationUCL Discovery (University College London) · 2022not yet assessed
-
β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease ↗Neurology · 2022 · PMID 35641311not yet assessed
-
An amyloid‐cognition composite score for estimating time‐consistent biomarker trajectories across the Alzheimer’s continuum ↗Alzheimer s & Dementia · 2022not yet assessed
-
Amyloid‐associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer ↗Alzheimer s & Dementia · 2022not yet assessed
-
Earlier Alzheimer's disease onset is associated with a shift of tau pathology towards brain hubs which facilitates tau spreading ↗Alzheimer s & Dementia · 2022not yet assessed
-
Earlier Alzheimer's disease onset is associated with a shift of tau pathology towards brain hubs which facilitates tau spreading ↗Alzheimer s & Dementia · 2022not yet assessed
-
Best combination of CSF biomarkers for predicting cognitive decline and clinical progression: A multi‐cohort study ↗Alzheimer s & Dementia · 2022not yet assessed
-
Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance ↗medRxiv · 2022not yet assessed
-
not yet assessed
-
Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle loads ↗medRxiv · 2022not yet assessed
-
Plasma pTau-217 in preclinical Alzheimer’s disease ↗medRxiv · 2022not yet assessed
-
not yet assessed
-
Reducing unnecessary tau-PET scans in a memory clinic setting via blood-based biomarker screening ↗Research Square · 2022not yet assessed
-
Polygenic risk of type 2 diabetes is associated with Vascular Dementia but not with Alzheimer's Disease: a Prospective Cohort Study ↗Research Square · 2022not yet assessed
-
Microglial activation might protect against accumulation of Aβ and tau aggregates over time in non‐demented Aβ‐positive individuals ↗Alzheimer s & Dementia · 2022not yet assessed
-
Medial temporal lobe subregional atrophy patterns in early‐ and late‐onset amnestic Alzheimer’s disease ↗Alzheimer s & Dementia · 2022not yet assessed
-
Age‐related tau‐PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults ↗Alzheimer s & Dementia · 2022not yet assessed
-
Medial temporal lobe subregional atrophy patterns in early‐ and late‐onset amnestic Alzheimer’s disease ↗Alzheimer s & Dementia · 2022not yet assessed
-
Age‐related tau‐PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults ↗Alzheimer s & Dementia · 2022not yet assessed
-
Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 to detect AD related outcomes using fully automated immunoassays ↗Alzheimer s & Dementia · 2022not yet assessed
-
Amyloid‐associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer ↗Alzheimer s & Dementia · 2022not yet assessed
-
Comparison of group‐level and individualized ROIs for predicting change in longitudinal tau‐PET in preclinical and prodromal AD ↗Alzheimer s & Dementia · 2022not yet assessed
-
Association Between EEG Patterns and Serum Neurofilament Light After Cardiac Arrest ↗Neurology · 2022 · PMID 35470143not yet assessed
-
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease ↗Brain · 2021 · PMID 34259835not yet assessed
-
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study ↗The Lancet Neurology · 2021 · PMID 34418401not yet assessed
-
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures ↗Nature Medicine · 2021 · PMID 34031605not yet assessed
-
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease ↗Alzheimer s & Dementia · 2021 · PMID 33491853not yet assessed
-
Blood‐based biomarkers for Alzheimer's disease ↗EMBO Molecular Medicine · 2021 · PMID 34859598not yet assessed
-
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease ↗JAMA Neurology · 2021 · PMID 34180956not yet assessed
-
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment ↗Alzheimer s Research & Therapy · 2021 · PMID 33773595not yet assessed
-
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations ↗Nature Communications · 2021 · PMID 34117234not yet assessed
-
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau ↗EMBO Molecular Medicine · 2021 · PMID 33949133not yet assessed
-
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory ↗Brain · 2021 · PMID 33725124not yet assessed
-
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau ↗Alzheimer s & Dementia · 2021 · PMID 34151519not yet assessed
-
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers ↗European Journal of Nuclear Medicine and Molecular Imaging · 2021 · PMID 33677733not yet assessed
-
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease ↗Translational Psychiatry · 2021 · PMID 33500386not yet assessed
-
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease ↗JAMA Neurology · 2021 · PMID 34928318not yet assessed
-
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects ↗Brain · 2021 · PMID 34077494not yet assessed
-
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers ↗EMBO Molecular Medicine · 2021 · PMID 34254442not yet assessed
-
Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays ↗Neurology · 2021 · PMID 34493616not yet assessed
-
Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest ↗Intensive Care Medicine · 2021 · PMID 34417831not yet assessed
-
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease ↗Current Opinion in Neurology · 2021 · PMID 33470669not yet assessed
-
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis ↗European Journal of Nuclear Medicine and Molecular Imaging · 2021 · PMID 34041562not yet assessed
-
Preoperative sleep quality and adverse pain outcomes after total hip arthroplasty ↗European Journal of Pain · 2021 · PMID 33682177not yet assessed
-
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework ↗European Journal of Nuclear Medicine and Molecular Imaging · 2021 · PMID 33674895not yet assessed
-
Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition ↗Scientific Reports · 2021 · PMID 33479445not yet assessed
-
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ‐associated tau accumulation and cognitive decline ↗Alzheimer s & Dementia · 2021 · PMID 34060233not yet assessed
-
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts ↗European Journal of Nuclear Medicine and Molecular Imaging · 2021 · PMID 33398408not yet assessed
-
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease ↗Scientific Reports · 2021 · PMID 34615922not yet assessed
-
Perceived walking difficulties in Parkinson’s disease – predictors and changes over time ↗BMC Geriatrics · 2021 · PMID 33794786not yet assessed
-
Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis ↗Pain Practice · 2021 · PMID 34143556not yet assessed
-
Creatinine and body mass index influence on plasma amyloid ratio, p‐tau217 and neurofilament light ↗Alzheimer s & Dementia · 2021not yet assessed
-
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory ↗Alzheimer s & Dementia · 2021not yet assessed
-
Prediction of future Alzheimer’s disease dementia using plasma phospho‐tau combined with other accessible measures ↗Alzheimer s & Dementia · 2021not yet assessed
-
Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers ↗Alzheimer s & Dementia · 2021not yet assessed
-
The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ‐associated tau accumulation and cognitive decline ↗Alzheimer s & Dementia · 2021not yet assessed
-
Associations between longitudinal neuropsychiatric symptoms and biomarkers of beta‐amyloid, tau, neurodegeneration, and cognitive decline ↗Alzheimer s & Dementia · 2021not yet assessed
-
Plasma glial fibrillary acidic protein is an early and specific marker of amyloid‐β pathology in Alzheimer’s disease ↗Alzheimer s & Dementia · 2021not yet assessed
-
Effects of APOE genotype, age and sex on cerebrospinal fluid biomarkers measured with NeuroToolKit in the Longitudinal Swedish Biofinder Cohort ↗Alzheimer s & Dementia · 2021not yet assessed
-
Soluble P‐tau217 reflects both amyloid and tau pathology in the human brain and mediates the association of amyloid with neocortical tau ↗Alzheimer s & Dementia · 2021not yet assessed
-
Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer’s disease ↗Alzheimer s & Dementia · 2021not yet assessed
-
Tau PET as a prognostic marker in preclinical and prodromal Alzheimer’s disease ↗Alzheimer s & Dementia · 2021not yet assessed
-
Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P‐tau181, P‐tau217 and P‐tau231 assays ↗Alzheimer s & Dementia · 2021not yet assessed
-
Mapping genetic determinants of 184 circulating proteins in 26,494 individuals to connect proteins and diseases ↗medRxiv · 2021not yet assessed
-
Plasma glial fibrillary acidic protein is an early marker of Aβ pathology in Alzheimer’s disease ↗medRxiv · 2021not yet assessed
-
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19 ↗medRxiv · 2021 · PMID 33851187not yet assessed
-
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures ↗Research Square · 2021not yet assessed
-
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau ↗Research Square · 2021not yet assessed
-
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies ↗Nature Communications · 2021 · PMID 33398024not yet assessed
-
not yet assessed
-
CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators ↗medRxiv · 2021not yet assessed
-
Independent information from PET, CSF and plasma biomarkers of tau pathology in Alzheimer’s disease ↗bioRxiv (Cold Spring Harbor Laboratory) · 2021not yet assessed
-
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease ↗Research Square · 2021not yet assessed
-
Amyloid‐β accumulation is independently related to executive function in cognitively unimpaired adults ↗Alzheimer s & Dementia · 2021not yet assessed
-
Unravelling drivers of age‐ and beta‐amyloid‐related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults ↗Alzheimer s & Dementia · 2021not yet assessed
-
Genetic Effects on Longitudinal Cognitive Decline During the Early Stages of Alzheimer's Disease ↗Research Square · 2021not yet assessed
-
Potential drivers of age‐ and beta‐amyloid‐related neurodegeneration in early and late Alzheimer’s Disease regions in cognitively normal older adults ↗Alzheimer s & Dementia · 2021not yet assessed
-
Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions ↗Alzheimer s & Dementia · 2021not yet assessed
-
Biomarker driven enrichment strategies for tau pathology in AD clinical trials ↗Alzheimer s & Dementia · 2021not yet assessed
-
Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment ↗Lund University Publications (Lund University) · 2021not yet assessed
-
Ability of tau‐PET, phospho‐tau217, NfL and cortical thickness to predict short‐term cognitive decline in early symptomatic Alzheimer’s disease ↗Alzheimer s & Dementia · 2021not yet assessed
-
Genetic interaction study of Alzheimer's disease quantitative biomarkers : A polygenic risk score analysis and evaluation ↗Rare & Special e-Zone (The Hong Kong University of Science and Technology) · 2021not yet assessed
-
Perceived walking difficulties in Parkinson’s disease – predictors and changes over time ↗Research Square · 2021not yet assessed
-
Genetic Effects on Longitudinal Cognitive Decline During the Early Stages of Alzheimer's Disease ↗Research Square · 2021not yet assessed
-
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders ↗JAMA · 2020 · PMID 32722745not yet assessed
-
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts ↗The Lancet Neurology · 2020 · PMID 32333900not yet assessed
-
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia ↗Nature Medicine · 2020 · PMID 32123385not yet assessed
-
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease ↗Nature Communications · 2020 · PMID 32246036not yet assessed
-
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease ↗JAMA Neurology · 2020 · PMID 33165506not yet assessed
-
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease ↗Science Advances · 2020 · PMID 32426454not yet assessed
-
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease ↗Brain · 2020 · PMID 33068398not yet assessed
-
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders ↗JAMA Neurology · 2020 · PMID 32391858not yet assessed
-
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease ↗Brain · 2020 · PMID 33279949not yet assessed
-
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations ↗Nature Aging · 2020 · PMID 37117993not yet assessed
-
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects ↗Brain · 2020 · PMID 33439987not yet assessed
-
The implications of different approaches to define AT(N) in Alzheimer disease ↗Neurology · 2020 · PMID 32398359not yet assessed
-
Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease ↗Neurology · 2020 · PMID 33046608not yet assessed
-
Performance of a guideline-recommended algorithm for prognostication of poor neurological outcome after cardiac arrest ↗Intensive Care Medicine · 2020 · PMID 32494928not yet assessed
-
The A4 study: β ‐amyloid and cognition in 4432 cognitively unimpaired adults ↗Annals of Clinical and Translational Neurology · 2020 · PMID 32315118not yet assessed
-
Relevance of biomarkers across different neurodegenerative diseases ↗Alzheimer s Research & Therapy · 2020 · PMID 32404143not yet assessed
-
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies ↗Nature Communications · 2020 · PMID 33288742not yet assessed
-
Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients ↗Resuscitation · 2020 · PMID 32445783not yet assessed
-
Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment ↗JAMA Neurology · 2020 · PMID 33044487not yet assessed
-
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg ↗Alzheimer s Research & Therapy · 2020 · PMID 32111242not yet assessed
-
The impact of demographic, clinical, genetic, and imaging variables on tau PET status ↗European Journal of Nuclear Medicine and Molecular Imaging · 2020 · PMID 33215319not yet assessed
-
Time between milestone events in the Alzheimer's disease amyloid cascade ↗NeuroImage · 2020 · PMID 33359337not yet assessed
-
Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease ↗Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2020 · PMID 32995466not yet assessed
-
Comparing progression biomarkers in clinical trials of early Alzheimer’s disease ↗Annals of Clinical and Translational Neurology · 2020 · PMID 32779869not yet assessed
-
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease ↗Annals of Clinical and Translational Neurology · 2020 · PMID 33249783not yet assessed
-
CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers ↗Scientific Reports · 2020 · PMID 32427856not yet assessed
-
The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People ↗The Journals of Gerontology Series A · 2020 · PMID 32506119not yet assessed
-
Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype ↗Pain · 2020 · PMID 32384383not yet assessed
-
White matter lesions are associated with CSF biomarkers of neuroinflammation in prodromal Alzheimer’s disease ↗Alzheimer s & Dementia · 2020not yet assessed
-
Mild behavioral impairment is predictive of tau deposition in the earliest stages of Alzheimer's disease ↗Alzheimer s & Dementia · 2020not yet assessed
-
Acute reduction of cerebrospinal fluid volume prior to spinal anesthesia: implications for sensory block extent ↗Minerva Anestesiologica · 2020 · PMID 32013330not yet assessed
-
Plasma phospho‐tau217 is a potential early diagnostic and prognostic biomarker of Alzheimer’s disease ↗Alzheimer s & Dementia · 2020not yet assessed
-
Phospho‐tau217 and phospho‐tau181 in plasma and CSF as biomarkers for Alzheimer’s disease ↗Alzheimer s & Dementia · 2020not yet assessed
-
Alzheimer’s disease biomarker roadmap 2020: Fluid biomarkers ↗Alzheimer s & Dementia · 2020not yet assessed
-
The accumulation rate of tau aggregates is higher in females and younger individuals ↗Alzheimer s & Dementia · 2020not yet assessed
-
Longitudinal [18F]RO948 PET SUVR is associated with Aβ accumulation and baseline tau pathology ↗Alzheimer s & Dementia · 2020not yet assessed
-
Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimer’s disease ↗Alzheimer s & Dementia · 2020not yet assessed
-
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease ↗medRxiv · 2020not yet assessed
-
Correction to: Relevance of biomarkers across different neurodegenerative diseases ↗Alzheimer s Research & Therapy · 2020 · PMID 32517788not yet assessed
-
Plasma Glial Fibrillary Acidic Protein Detects Alzheimer Pathology and Predicts Future Conversion to Alzheimer Dementia in Patients With Mild Cognitive Impairment ↗Research Square · 2020not yet assessed
-
Time between milestone events in the Alzheimer’s disease amyloid cascade ↗bioRxiv (Cold Spring Harbor Laboratory) · 2020not yet assessed
-
Perceived walking difficulties in Parkinson’s disease – predictors and changes over time ↗Research Square · 2020not yet assessed
-
Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment ↗medRxiv · 2020not yet assessed
-
Soluble P-tau217 reflects both amyloid and tau pathology in the human brain and mediates the association of amyloid with neocortical tau ↗Research Square · 2020not yet assessed
-
Plasma‐based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease ↗Alzheimer s & Dementia · 2020not yet assessed
-
Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer’s disease in the absence of AT(N) classification as the reference standard ↗Alzheimer s & Dementia · 2020not yet assessed
-
Genome‐wide polygenic risk scores for identification of gene therapeutic target ↗Alzheimer s & Dementia · 2020not yet assessed
-
Comparison of 18F‐Flortaucipir visual assessment, SUVR quantification and CSF pTau for defining T‐status in the AT(N) framework ↗Alzheimer s & Dementia · 2020not yet assessed
-
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology ↗JAMA Neurology · 2019 · PMID 31206160not yet assessed
-
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease ↗JAMA Neurology · 2019 · PMID 31009028not yet assessed
-
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status ↗JAMA Neurology · 2019 · PMID 31233127not yet assessed
-
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease ↗EMBO Molecular Medicine · 2019 · PMID 31709776not yet assessed
-
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease ↗Neurology · 2019 · PMID 30626656not yet assessed
-
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease ↗Acta Neuropathologica Communications · 2019 · PMID 31694701not yet assessed
-
Staging β -Amyloid Pathology With Amyloid Positron Emission Tomography ↗JAMA Neurology · 2019 · PMID 31314895not yet assessed
-
Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays ↗Scientific Reports · 2019 · PMID 31836810not yet assessed
-
Apathy and anxiety are early markers of Alzheimer's disease ↗Neurobiology of Aging · 2019 · PMID 31735378not yet assessed
-
Determining clinically meaningful decline in preclinical Alzheimer disease ↗Neurology · 2019 · PMID 31289148not yet assessed
-
Predicting diagnosis and cognition with 18 F‐AV‐1451 tau PET and structural MRI in Alzheimer's disease ↗Alzheimer s & Dementia · 2019 · PMID 30639421not yet assessed
-
Associations between partial pressure of oxygen and neurological outcome in out-of-hospital cardiac arrest patients: an explorative analysis of a randomized trial ↗Critical Care · 2019 · PMID 30691510not yet assessed
-
Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders ↗Movement Disorders · 2019 · PMID 31837067not yet assessed
-
β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly ↗Scientific Reports · 2019 · PMID 31371787not yet assessed
-
Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults ↗Neurobiology of Aging · 2019 · PMID 31437719not yet assessed
-
Predictive Factors of Concerns about Falling in People with Parkinson’s Disease: A 3-Year Longitudinal Study ↗Parkinson s Disease · 2019 · PMID 31915520not yet assessed
-
Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest ↗Biomarkers · 2019 · PMID 31017476not yet assessed
-
P3‐303: DIFFERENT APPROACHES TO DEFINE ATN IN ALZHEIMER'S DISEASE ↗Alzheimer s & Dementia · 2019not yet assessed
-
P3‐394: TIME BETWEEN MILESTONE EVENTS IN THE ALZHEIMER'S DISEASE AMYLOID CASCADE ↗Alzheimer s & Dementia · 2019not yet assessed
-
Primary fatty amides are potential plasma biomarkers for AD ↗Nature Reviews Neurology · 2019 · PMID 31253949not yet assessed
-
F4‐02‐04: CSF AND PET MEASURES FOR TAU IN DIFFERENT STAGES OF ALZHEIMER'S DISEASE ↗Alzheimer s & Dementia · 2019not yet assessed
-
DT‐01‐04: DIAGNOSTIC PERFORMANCE OF [18F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER‐2 STUDY ↗Alzheimer s & Dementia · 2019not yet assessed
-
P4‐536: CEREBROSPINAL FLUID BIOMARKERS FOR AMYLOID AND TAU USING FULLY AUTOMATED ASSAYS: ASSOCIATIONS WITH NEUROPATHOLOGY ↗Alzheimer s & Dementia · 2019not yet assessed
-
P4‐278: STAGING β‐AMYLOID PATHOLOGY WITH 18F‐FLORBETAPIR PET IMAGING ↗Alzheimer s & Dementia · 2019not yet assessed
-
F2‐07‐03: FULLY AUTOMATED PLASMA ASSAYS AS SCREENING TESTS FOR EARLY ALZHEIMER‐RELATED β‐AMYLOID PATHOLOGY ↗Alzheimer s & Dementia · 2019not yet assessed
-
Changes in fear of falling: a 3-year prospective studyLund University Publications (Lund University) · 2019not yet assessed
-
P.780 Apathy and anxiety are early markers of Alzheimer's disease ↗European Neuropsychopharmacology · 2019not yet assessed
-
Additional file 1: of Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimerâ s disease ↗Figshare · 2019not yet assessed
-
Discriminative Accuracy of [ 18 F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders ↗JAMA · 2018 · PMID 30326496not yet assessed
-
CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease ↗Neurology · 2018 · PMID 30054439not yet assessed
-
Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest ↗JAMA Neurology · 2018 · PMID 30383090not yet assessed
-
Biomarkers for tau pathology ↗Molecular and Cellular Neuroscience · 2018 · PMID 30529601not yet assessed
-
Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia ↗Annals of Neurology · 2018 · PMID 30255971not yet assessed
-
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable ↗Alzheimer s & Dementia · 2018 · PMID 29653607not yet assessed
-
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review ↗Alzheimer s & Dementia · 2018 · PMID 29940161not yet assessed
-
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study ↗Alzheimer s Research & Therapy · 2018 · PMID 30086796not yet assessed
-
Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease ↗Neurology · 2018 · PMID 29321235not yet assessed
-
Data‐driven approaches for tau‐PET imaging biomarkers in Alzheimer's disease ↗Human Brain Mapping · 2018 · PMID 30368979not yet assessed
-
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease ↗Alzheimer s & Dementia · 2018 · PMID 29601787not yet assessed
-
Carbon dioxide dynamics in relation to neurological outcome in resuscitated out-of-hospital cardiac arrest patients: an exploratory Target Temperature Management Trial substudy ↗Critical Care · 2018 · PMID 30119692not yet assessed
-
Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients ↗Mitochondrion · 2018 · PMID 30004022not yet assessed
-
Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment ↗International Journal of Geriatric Psychiatry · 2018 · PMID 29953668not yet assessed
-
Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease ↗Neurobiology of Aging · 2018 · PMID 30107289not yet assessed
-
Apolipoprotein E genotypes and longevity across dementia disorders ↗Alzheimer s & Dementia · 2018 · PMID 29548722not yet assessed
-
O3‐04‐01: ASSOCIATIONS BETWEEN TAU, Aβ AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE ↗Alzheimer s & Dementia · 2018not yet assessed
-
Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia ↗Neurodegenerative Diseases · 2018not yet assessed
-
DT‐02‐04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA Aβ BIOMARKER ASSAYS ↗Alzheimer s & Dementia · 2018not yet assessed
-
Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer’s disease ↗bioRxiv (Cold Spring Harbor Laboratory) · 2018not yet assessed
-
P1‐430: EFFECTS OF APOE ε4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE ↗Alzheimer s & Dementia · 2018not yet assessed
-
DT‐01‐01: DEVELOPMENT OF AB, TAU AND COGNITIVE CHANGES DURING THE TIME COURSE OF SPORADIC ALZHEIMER'S DISEASE ↗Alzheimer s & Dementia · 2018not yet assessed
-
O2‐09‐01: CSF, PLASMA AND MRI BIOMARKER TRAJECTORIES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE ↗Alzheimer s & Dementia · 2018not yet assessed
-
P1‐279: BIMODAL DISTRIBUTION OF THE CSF Aβ42/Aβ40 RATIO IN CLINICAL LABORATORY PRACTICE ↗Alzheimer s & Dementia · 2018not yet assessed
-
O3‐14‐05: ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION ↗Alzheimer s & Dementia · 2018not yet assessed
-
DT‐01‐06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS ↗Alzheimer s & Dementia · 2018not yet assessed
-
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A reviewUCL Discovery (University College London) · 2018not yet assessed
-
TauRUS Tau-PET Atlas (MNI space, 1 mm) ↗Figshare · 2018not yet assessed
-
TauRUS Tau-PET Atlas (MNI space, 1 mm) ↗Figshare · 2018not yet assessed
-
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease ↗JAMA Neurology · 2017 · PMID 28346578not yet assessed
-
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity ↗Nature Communications · 2017 · PMID 29089479not yet assessed
-
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers ↗The Lancet Neurology · 2017 · PMID 28721928not yet assessed
-
18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease ↗EMBO Molecular Medicine · 2017 · PMID 28743782not yet assessed
-
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia ↗JAMA Psychiatry · 2017 · PMID 29188296not yet assessed
-
Serum tau and neurological outcome in cardiac arrest ↗Annals of Neurology · 2017 · PMID 28981963not yet assessed
-
Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework ↗Neurobiology of Aging · 2017 · PMID 28317649not yet assessed
-
CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients ↗Neurobiology of Aging · 2017 · PMID 28779628not yet assessed
-
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease ↗Frontiers in Neuroscience · 2017 · PMID 28567001not yet assessed
-
Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival ↗Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · PMID 28631955not yet assessed
-
A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease ↗Scientific Reports · 2017 · PMID 29042634not yet assessed
-
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway ↗Molecular Neurodegeneration · 2017 · PMID 28219449not yet assessed
-
Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression ↗American Journal of Geriatric Psychiatry · 2017 · PMID 28629965not yet assessed
-
Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations ↗Alzheimer s Research & Therapy · 2017 · PMID 29061195not yet assessed
-
Amyloid pathology in the progression to mild cognitive impairment ↗Neurobiology of Aging · 2017 · PMID 29353101not yet assessed
-
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study ↗Journal of Neuroinflammation · 2017 · PMID 28962579not yet assessed
-
[P4–525]: DATA‐DRIVEN TAU‐PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER's DISEASE ↗Alzheimer s & Dementia · 2017not yet assessed
-
[O2–01–02]: THE AMYLOID RISK SCORE: AN ACCURATE AND CROSS‐VALIDATED METHOD THAT PREDICTS CEREBRAL β‐AMYLOIDOSIS ↗Alzheimer s & Dementia · 2017not yet assessed
-
[O2–05–05]: EFFECTS OF APOE E4 IN PRODROMAL ALZHEIMER's DISEASE ↗Alzheimer s & Dementia · 2017not yet assessed
-
[P3–132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY ↗Alzheimer s & Dementia · 2017not yet assessed
-
[P4–197]: EMERGING AMYLOID PATHOLOGY ↗Alzheimer s & Dementia · 2017not yet assessed
-
[P3–075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS ↗Alzheimer s & Dementia · 2017not yet assessed
-
Additional file 1: Figure S1. of Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway ↗Figshare · 2017not yet assessed
-
Cerebrospinal fluid neurofilament light protein as a diagnostic and prognostic biomarker in mitochondrial diseases with CNS involvement ↗European Journal of Paediatric Neurology · 2017not yet assessed
-
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.eScholarship (California Digital Library) · 2017not yet assessed
-
[P1–575]: PREVALENCE OF THE APOLIPOPROTEIN E ε4 ALLELE IN AMYLOID‐β POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER's DISEASE ↗Alzheimer s & Dementia · 2017not yet assessed
-
Plasma tau in Alzheimer disease ↗Neurology · 2016 · PMID 27694257not yet assessed
-
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease ↗Annals of Clinical and Translational Neurology · 2016 · PMID 27042676not yet assessed
-
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography ↗Brain · 2016 · PMID 26936941not yet assessed
-
Serum neurofilament light protein predicts clinical outcome in traumatic brain injury ↗Scientific Reports · 2016 · PMID 27819296not yet assessed
-
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease ↗EMBO Molecular Medicine · 2016 · PMID 27534871not yet assessed
-
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development ↗Alzheimer s & Dementia Translational Research & Clinical Interventions · 2016 · PMID 29067320not yet assessed
-
Myo-inositol changes precede amyloid pathology and relate toAPOEgenotype in Alzheimer disease ↗Neurology · 2016 · PMID 27164711not yet assessed
-
Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease ↗Journal of Neurology Neurosurgery & Psychiatry · 2016 · PMID 26746185not yet assessed
-
Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis ↗Nature Communications · 2016 · PMID 26948379not yet assessed
-
Assessing risk for preclinical β‐amyloid pathology with APOE , cognitive, and demographic information ↗Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2016 · PMID 27722193not yet assessed
-
Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology ↗Neurology · 2016 · PMID 27164667not yet assessed
-
Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment ↗Neurobiology of Aging · 2016 · PMID 27710807not yet assessed
-
Cerebrospinal fluid Aβ42/Aβ40 and Aβ42/Aβ38 as biomarkers of Alzheimer’s disease ↗Neurobiology of Aging · 2016not yet assessed
-
Maturity of Aβ42, tau, and phospho-tau in the cerebrospinal fluid as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework ↗Neurobiology of Aging · 2016not yet assessed
-
P1‐338: Assessing Risk for Preclinical β‐Amyloid Pathology with APOE, Cognitive and Demographic Information ↗Alzheimer s & Dementia · 2016not yet assessed
-
Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis? ↗Brain · 2016 · PMID 27383527not yet assessed
-
Classification Performance of Convolutional Neural NetworksKTH Publication Database DiVA (KTH Royal Institute of Technology) · 2016not yet assessed
-
CSF analysis detect cerebral β-amyloid accumulation earlier than amyloid PET ↗Neurobiology of Aging · 2016not yet assessed
-
O2‐08‐06: CSF Analysis Detects Cerebral B‐Amyloid Accumulation Earlier than Amyloid Pet ↗Alzheimer s & Dementia · 2016not yet assessed
-
P2‐142: Comparison of T‐Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease ↗Alzheimer s & Dementia · 2016not yet assessed
-
IC‐P‐002: : Roadmap to The Biomarker‐Based Diagnosis of Alzheimer’s Disease ↗Alzheimer s & Dementia · 2016not yet assessed
-
O1‐05‐01: Increased Amyloidogenic app Processing in Apoe E4‐Negative Individuals with Cerebral B‐Amyloidosis ↗Alzheimer s & Dementia · 2016not yet assessed
-
P4‐339: Early‐ and Late‐Onset Alzheimer’S Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]F‐AV‐1451 TAU Positron Emission Tomography ↗Alzheimer s & Dementia · 2016not yet assessed
-
Increased amyloidogenic APP processing in APOE epsilon 4-negative individuals with cerebral beta-amyloidosisUCL Discovery (University College London) · 2016not yet assessed
-
P3‐193: Serum Neurofilament Light Protein Predicts Clinical Outcome in Traumatic Brain Injury ↗Alzheimer s & Dementia · 2016not yet assessed
-
P2‐167: Roadmap to the Biomarker‐Based Diagnosis of Alzheimer's Disease ↗Alzheimer s & Dementia · 2016not yet assessed
-
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia ↗JAMA · 2015 · PMID 25988462not yet assessed
-
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression ↗JAMA Neurology · 2015 · PMID 26524180not yet assessed
-
Amyloid biomarkers in Alzheimer's disease ↗Trends in Pharmacological Sciences · 2015 · PMID 25840462not yet assessed
-
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease ↗Neurology · 2015 · PMID 26354982not yet assessed
-
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease ↗Brain · 2015 · PMID 26373605not yet assessed
-
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 ↗Alzheimer s & Dementia · 2015 · PMID 26194310not yet assessed
-
Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia ↗Brain · 2015 · PMID 26133663not yet assessed
-
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study ↗Alzheimer s & Dementia · 2015 · PMID 25804998not yet assessed
-
Revolutionizing Alzheimer's disease and clinical trials through biomarkers ↗Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2015 · PMID 27239522not yet assessed
-
Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease ↗Neurobiology of Aging · 2015 · PMID 25990306not yet assessed
-
Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia ↗American Journal of Geriatric Psychiatry · 2015 · PMID 26238228not yet assessed
-
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls ↗JAMA Neurology · 2015 · PMID 25775167not yet assessed
-
Interaction of Cigarette Smoking History WithAPOEGenotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders ↗Nicotine & Tobacco Research · 2015 · PMID 25847292not yet assessed
-
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease ↗Annals of Clinical and Translational Neurology · 2015 · PMID 26000325not yet assessed
-
Serum visinin-like protein-1 in concussed professional ice hockey players ↗Brain Injury · 2015 · PMID 25955117not yet assessed
-
Brain structure and function as mediators of the effects of amyloid on memory ↗Neurology · 2015 · PMID 25681451not yet assessed
-
Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair ↗Neurochemistry International · 2015 · PMID 26682901not yet assessed
-
Benchmarking biomarker‐based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem ↗Alzheimer s & Dementia · 2015 · PMID 26079415not yet assessed
-
O1‐07‐01: Diagnostic comparison of regional amyloid PET and different CSF biomarker assays for identifying early Alzheimer's disease ↗Alzheimer s & Dementia · 2015not yet assessed
-
Cerebral amyloid burden and Alzheimer's disease subtypes – does localization information matter? ↗European Journal of Neurology · 2015 · PMID 26177335not yet assessed
-
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease - eScholarship2015not yet assessed
-
S5‐01‐03: CSF biomarkers versus PET biomarkers ↗Alzheimer s & Dementia · 2015not yet assessed
-
P4‐135: Inclusion criteria and cognitive responses to optimize trials in Alzheimer's disease ↗Alzheimer s & Dementia · 2015not yet assessed
-
JAMA Paper supplement2015not yet assessed
-
Smoking and increased Alzheimer's disease risk: A review of potential mechanisms ↗Alzheimer s & Dementia · 2014 · PMID 24924665not yet assessed
-
The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? ↗Alzheimer s & Dementia · 2014 · PMID 24721526not yet assessed
-
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival ↗Neurology · 2014 · PMID 25339208not yet assessed
-
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease ↗Brain · 2014 · PMID 25541191not yet assessed
-
Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer’s disease and mild cognitive impairment ↗Brain · 2014 · PMID 24625697not yet assessed
-
Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease ↗JAMA Neurology · 2014 · PMID 24566866not yet assessed
-
Reporting standards for studies of diagnostic test accuracy in dementia ↗Neurology · 2014 · PMID 24944261not yet assessed
-
Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease ↗JAMA Psychiatry · 2014 · PMID 25162367not yet assessed
-
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease ↗Annals of Clinical and Translational Neurology · 2014 · PMID 25356425not yet assessed
-
Bidirectional links between Alzheimer's disease and Niemann–Pick type C disease ↗Neurobiology of Disease · 2014 · PMID 24907492not yet assessed
-
Understanding the cause of sporadic Alzheimer’s disease ↗Expert Review of Neurotherapeutics · 2014 · PMID 24852227not yet assessed
-
Emerging β-Amyloid Pathology and Accelerated Cortical Atrophy ↗JAMA Neurology · 2014 · PMID 24781145not yet assessed
-
Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms ↗Journal of Proteome Research · 2014 · PMID 24392642not yet assessed
-
The transitional association between β‐amyloid pathology and regional brain atrophy ↗Alzheimer s & Dementia · 2014 · PMID 25499535not yet assessed
-
Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid ↗Neurodegenerative Diseases · 2014 · PMID 24992945not yet assessed
-
β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage ↗Alzheimer s Research & Therapy · 2014 · PMID 25404952not yet assessed
-
CSF in Alzheimer's Disease ↗Advances in clinical chemistry · 2014 · PMID 25233613not yet assessed
-
Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down’s Syndrome ↗NeuroMolecular Medicine · 2014 · PMID 24740518not yet assessed
-
Cerebrospinal Fluid α-Synuclein and Lewy Body-Like Symptoms in Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease ↗Journal of Alzheimer s Disease · 2014 · PMID 25125463not yet assessed
-
History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress ↗Drug and Alcohol Dependence · 2014 · PMID 25037769not yet assessed
-
O2‐05‐02: AMYLOID BIOMARKERS FOR AD: CURRENT STATUS AND NOVEL FINDINGS ↗Alzheimer s & Dementia · 2014not yet assessed
-
P4‐137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA‐AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY ↗Alzheimer s & Dementia · 2014not yet assessed
-
O2‐05‐06: COMBINING CSF AB42 AND PET FLORBETAPIR TO PREDICT DIAGNOSIS, TAU, ATROPHY, AND COGNITION ↗Alzheimer s & Dementia · 2014not yet assessed
-
P3‐078: SERUM NEUROFILAMENT LIGHT PROTEIN AND VISIN‐LIKE PROTEIN‐1 IN CONCUSSED PROFESSIONAL ICE HOCKEY PLAYERS ↗Alzheimer s & Dementia · 2014not yet assessed
-
O1‐07‐03: EFFECTS OF AMYLOID STATUS AND AGE ON LONGITUDINAL REGIONAL BRAIN ATROPHY IN ELDERLY HEALTHY CONTROLS ↗Alzheimer s & Dementia · 2014not yet assessed
-
P2‐094: COMPARING THE DIAGNOSTIC ACCURACIES OF CSF Aβ42 AND PET FLORBETAPIR ↗Alzheimer s & Dementia · 2014not yet assessed
-
P4‐063: APOE GENOTYPE AND CSF Aβ42 IN COGNITIVELY HEALTHY INDIVIDUALS ↗Alzheimer s & Dementia · 2014not yet assessed
-
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia ↗Neurodegenerative Diseases · 2014not yet assessed
-
CSF biomarker variability in the Alzheimer's Association quality control program ↗Alzheimer s & Dementia · 2013 · PMID 23622690not yet assessed
-
Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease ↗NeuroMolecular Medicine · 2013 · PMID 24101586not yet assessed
-
Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease ↗Psychoneuroendocrinology · 2013 · PMID 23473966not yet assessed
-
CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders ↗Translational Psychiatry · 2013 · PMID 23962923not yet assessed
-
Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection ↗BMC Neurology · 2013 · PMID 23294475not yet assessed
-
Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults ↗Neurobiology of Aging · 2013 · PMID 24094581not yet assessed
-
Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples ↗Alzheimer s Research & Therapy · 2013 · PMID 24479774not yet assessed
-
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis ↗Journal of Neuroimmunology · 2013 · PMID 24125567not yet assessed
-
Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease ↗PLoS ONE · 2013 · PMID 24312390not yet assessed
-
Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage? ↗Clinical Chemistry and Laboratory Medicine (CCLM) · 2013 · PMID 23729569not yet assessed
-
Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter Study ↗Pediatric Neurology · 2013 · PMID 23827424not yet assessed
-
CSF biomarkers for Alzheimer’s pathology and the effect size of APOE ɛ4 ↗Molecular Psychiatry · 2013 · PMID 23419830not yet assessed
-
Cerebrospinal fluid biomarkers of β‐amyloid metabolism and neuronal damage in epileptic seizures ↗European Journal of Neurology · 2013 · PMID 24372994not yet assessed
-
Automated cerebrospinal fluid cell count — New reference ranges and evaluation of its clinical use in central nervous system infections ↗Clinical Biochemistry · 2013 · PMID 24275252not yet assessed
-
Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease ↗PLoS ONE · 2013 · PMID 24392009not yet assessed
-
Plasma Amyloid-β in Patients with Tangier Disease ↗Journal of Alzheimer s Disease · 2013 · PMID 23388172not yet assessed
-
P1–178: CSF biomarker variability in the Alzheimer's Association quality control program ↗Alzheimer s & Dementia · 2013not yet assessed
-
[Niemann-Pick type C disease. Rare but possible diagnosis in adult neurology and psychiatry]. ↗PubMed · 2013 · PMID 23745504not yet assessed
-
Coagulation of cerebrospinal fluid—the Nonne–Froin sign ↗Practical Neurology · 2013 · PMID 23487811not yet assessed
-
P1–061: CSF biomarkers for Alzheimer's pathology and the effect size of APOE‐ε4 ↗Alzheimer s & Dementia · 2013not yet assessed
-
O3–03–04: Protein biomarkers predicting longitudinal change in CSF beta‐amyloid 42 in cognitively healthy controls ↗Alzheimer s & Dementia · 2013not yet assessed
-
P3–101: Cerebral blood flow measured by arterial spin labeling magnetic resonance imaging: Regional reductions in early stages of Alzheimer's disease and comparisons with brain volume loss ↗Alzheimer s & Dementia · 2013not yet assessed
-
O3–08–06: Alterations in structure and perfusion in Alzheimer's disease–related brain areas depend on beta‐amyloid accumulation in healthy controls and MCI patients ↗Alzheimer s & Dementia · 2013not yet assessed
-
O1–09–06: The ‘CSF Alzheimer's profile’: Easily said, but what do we mean? ↗Alzheimer s & Dementia · 2013not yet assessed
-
["Fight against aging as a disease"]. ↗PubMed · 2013 · PMID 23451680not yet assessed
-
Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter Study (S25.002) ↗Neurology · 2013not yet assessed
-
Journal Watch: Our Panel of Experts Highlight the Most Important Research Articles Across the Spectrum of Topics Relevant to the Field of Neurodegenerative Disease Management ↗Neurodegenerative Disease Management · 2013not yet assessed
-
Journal Watch: Our Panel of Experts Highlight the Most Important Research Articles Across the Spectrum of Topics Relevant to the Field of Neurodegenerative Disease management. ↗Neurodegenerative Disease Management · 2013not yet assessed
-
Age and diagnostic performance of Alzheimer disease CSF biomarkers ↗Neurology · 2012 · PMID 22302554not yet assessed
-
Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium ↗Alzheimer s & Dementia · 2012 · PMID 23274154not yet assessed
-
Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment ↗Journal of Alzheimer s Disease · 2012 · PMID 22475796not yet assessed
-
An online nano‐LC‐ESI‐FTICR‐MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid ↗Journal of Mass Spectrometry · 2012 · PMID 22576872not yet assessed
-
Reference Measurement Procedures for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers: Definitions and Approaches With Focus on Amyloid β42 ↗Biomarkers in Medicine · 2012 · PMID 22917143not yet assessed
-
Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease ↗NeuroMolecular Medicine · 2012 · PMID 22350541not yet assessed
-
BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System ↗PLoS ONE · 2012 · PMID 22328928not yet assessed
-
Determining Cut-Points for Alzheimer’s Disease Biomarkers: Statistical Issues, Methods and Challenges ↗Biomarkers in Medicine · 2012 · PMID 22917141not yet assessed
-
Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS ↗PLoS ONE · 2012 · PMID 22880031not yet assessed
-
Mass Spectrometric Characterization of Amyloid-β Species in the 7PA2 Cell Model of Alzheimer's Disease ↗Journal of Alzheimer s Disease · 2012 · PMID 22886024not yet assessed
-
Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease ↗Psychoneuroendocrinology · 2012 · PMID 23159010not yet assessed
-
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis ↗Multiple Sclerosis Journal · 2012 · PMID 23069872not yet assessed
-
Amyloid-β metabolism in Niemann-Pick C disease models and patients ↗Metabolic Brain Disease · 2012 · PMID 22935999not yet assessed
-
Proficiency Testing Programs for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers ↗Biomarkers in Medicine · 2012 · PMID 22917142not yet assessed
-
Cerebrospinal fluid biomarkers in neurological diseases in children ↗European Journal of Paediatric Neurology · 2012 · PMID 23026858not yet assessed
-
Serum levels of LIGHT in MS ↗Multiple Sclerosis Journal · 2012 · PMID 23037546not yet assessed
-
The Accu-Chek Mobile blood glucose monitoring system used under controlled conditions meets ISO 15197 standards in the hands of diabetes patients ↗Scandinavian Journal of Clinical and Laboratory Investigation · 2012 · PMID 22900743not yet assessed
-
What is a Certified Reference Material? ↗Biomarkers in Medicine · 2012 · PMID 22917138not yet assessed
-
O1‐01‐02: Longitudinal measurements of cerebrospinal fluid biomarkers over four years in mild cognitive impairment ↗Alzheimer s & Dementia · 2012not yet assessed
-
P2‐072: The performance of Aβ5‐X isoforms as novel pharmacodynamic markers of BACE1 inhibition ↗Alzheimer s & Dementia · 2012not yet assessed
-
Our Experts Highlight the Most Important Research Articles Across the Spectrum of Topics Relevant to the Field of Neurodegenerative Disease Management ↗Neurodegenerative Disease Management · 2012not yet assessed
-
P1‐013: Cerebrospinal fluid profiles of Aβ‐related biomarkers in Alzheimer's disease ↗Alzheimer s & Dementia · 2012not yet assessed
-
Cerebrospinal Fluid Biomarkers to Monitor Treatment Effects in Alzheimer’s Disease and Related Conditions ↗Neurodegenerative Disease Management · 2012not yet assessed
-
S4‐02‐02: Cerebrospinal fluid biomarker standardization efforts ↗Alzheimer s & Dementia · 2012not yet assessed
-
P4‐082: The effects of apolipoprotein genotype on the diagnostic accuracy of cerebroispinal fluid biomarkers for Alzheimer's disease ↗Alzheimer s & Dementia · 2012not yet assessed
-
Isaksson HS The Accu-Chek Mobile glucose monitoring system Scand j of clinical and lab invest 20122012not yet assessed
-
Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management ↗Neurodegenerative Disease Management · 2012not yet assessed
-
Our Panel of Experts Highlight the Most Important Research Articles Across the Spectrum of Topics Relevant to the Field of Neurodegenerative Disease Management ↗Neurodegenerative Disease Management · 2012not yet assessed
-
Journal Watch: Our Panel of Experts Highlight the Most Important Research Articles Across the Spectrum of Topics Relevant to the Field of Neurodegenerative Disease Management ↗Neurodegenerative Disease Management · 2012not yet assessed
-
Journal Watch: Our Panel of Experts Highlight the Most Important Research Articles Across the Spectrum of Topics Relevant to the Field of Neurodegenerative Disease Management ↗Neurodegenerative Disease Management · 2012not yet assessed
-
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers ↗Alzheimer s & Dementia · 2011 · PMID 21784349not yet assessed
-
Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility ↗NeuroMolecular Medicine · 2011 · PMID 21567187not yet assessed
-
CSF biomarkers in neurodegenerative diseases ↗Clinical Chemistry and Laboratory Medicine (CCLM) · 2011 · PMID 21303297not yet assessed
-
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population ↗Journal of Alzheimer s Disease · 2011 · PMID 21297262not yet assessed
-
Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment ↗Current Pharmaceutical Design · 2011 · PMID 21728980not yet assessed
-
Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases ↗Frontiers in Aging Neuroscience · 2011 · PMID 21442044not yet assessed
-
Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study ↗Experimental Gerontology · 2011 · PMID 22210159not yet assessed
-
Miglustat Treatment May Reduce Cerebrospinal Fluid Levels of the Axonal Degeneration Marker Tau in Niemann–Pick Type C ↗JIMD Reports · 2011 · PMID 23430872not yet assessed
-
Biomarkers for Microglial Activation in Alzheimer′s Disease ↗International Journal of Alzheimer s Disease · 2011 · PMID 22114747not yet assessed
-
Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women ↗Clinical Endocrinology · 2011 · PMID 21521348not yet assessed
-
The N-terminal domain of α-dystroglycan, released as a 38kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis ↗Biochemical and Biophysical Research Communications · 2011 · PMID 21843510not yet assessed
-
[Automated cerebrospinal fluid cell count. A valuable contribution to diagnostics of brain diseases]. ↗PubMed · 2011 · PMID 22111239not yet assessed
-
Troponin T: more than acute myocardial infarction. ↗PubMed · 2011 · PMID 21612120not yet assessed
-
CSF biomarkers reflecting beta-amyloid and axonal pathology in Alzheimer's disease and related conditionsGothenburg University Publications Electronic Archive (Gothenburg University) · 2011not yet assessed
-
Growth factors in Parkinson's disease. ↗PubMed · 2011 · PMID 21614801not yet assessed
-
P1‐129: Cerebrospinal fluid markers of microglial activation and neuroinflammation in Alzheimer's disease ↗Alzheimer s & Dementia · 2011not yet assessed
-
P4‐317: Amyloid metabolism in Niemann‐Pick type C disease ↗Alzheimer s & Dementia · 2011not yet assessed
-
Research Highlights ↗Biomarkers in Medicine · 2011 · PMID 21473724not yet assessed
-
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersDigital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) · 2011not yet assessed
-
Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall ↗Clinical Chemistry and Laboratory Medicine (CCLM) · 2010 · PMID 20201744not yet assessed
-
γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C ↗Neurology · 2010 · PMID 21205675not yet assessed
-
To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease ↗International Journal of Alzheimer s Disease · 2010 · PMID 20798843not yet assessed
-
Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism ↗BMC Neurology · 2010 · PMID 20569437not yet assessed
-
Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease ↗International Journal of Alzheimer s Disease · 2010 · PMID 20721354not yet assessed
-
Proteomic profiling of cerebrospinal fluid in parkinsonian disorders ↗Parkinsonism & Related Disorders · 2010 · PMID 20620095not yet assessed
-
Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain ↗Journal of Alzheimer s Disease · 2010 · PMID 20413871not yet assessed
-
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease ↗Alzheimer s Research & Therapy · 2010 · PMID 21122172not yet assessed
-
Biochemical Markers in Alzheimer's Disease Clinical Trials ↗Biomarkers in Medicine · 2010 · PMID 20387305not yet assessed
-
Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems ↗International Journal of Alzheimer s Disease · 2010 · PMID 21487447not yet assessed
-
P1‐275: Increased cerebrospinal fluid amyloid β levels in Niemann‐Pick disease patients: Implications for Alzheimer's disease ↗Alzheimer s & Dementia · 2010not yet assessed
-
P3‐206: Convergence of chromogranin and amyloid metabolism in the brain ↗Alzheimer s & Dementia · 2010not yet assessed
-
F2‐01‐02: The standardization of CSF biomarkers for Alzheimer's disease: A model for imaging ↗Alzheimer s & Dementia · 2010not yet assessed
-
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment ↗JAMA · 2009 · PMID 19622817not yet assessed
-
CSF Biomarkers ↗Annals of the New York Academy of Sciences · 2009 · PMID 19906258not yet assessed
-
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis ↗Multiple Sclerosis Journal · 2009 · PMID 19153172not yet assessed
-
Elevated cerebrospinal fluid levels of prostaglandin E2 and 15‐(S)‐hydroxyeicosatetraenoic acid in multiple sclerosis ↗Journal of Internal Medicine · 2009 · PMID 19019188not yet assessed
-
Converging molecular pathways in human neural development and degeneration ↗Neuroscience Research · 2009 · PMID 19961883not yet assessed
-
Alzheimer's Disease and CSF Biomarkers: Key Challenges for Broad Clinical Applications ↗Biomarkers in Medicine · 2009 · PMID 20477711not yet assessed
-
Future Screening for Incipient Alzheimer’s Disease – The Influence of Prevalence on Test Performance ↗European Neurology · 2009 · PMID 19602894not yet assessed
-
CSFBiomarkersandIncipientAlzheimerDisease in Patients With Mild Cognitive Impairment2009not yet assessed
-
O4‐02‐08: Altered amyloid metabolism in neuroinflammation ↗Alzheimer s & Dementia · 2009not yet assessed
-
Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years ↗Journal of Alzheimer s Disease · 2007 · PMID 18057559not yet assessed
-
Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis ↗Journal of Neurochemistry · 2007 · PMID 17953655not yet assessed
-
Discontinuation of proton pump inhibitors in patients on long‐term therapy: a double‐blind, placebo‐controlled trial ↗Alimentary Pharmacology & Therapeutics · 2006 · PMID 16948806not yet assessed
-
Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients ↗Neuroscience Letters · 2006 · PMID 17227694not yet assessed
-
Homework Assignments in Hybrid and Embedded ControlKTH Publication Database DiVA (KTH Royal Institute of Technology) · 2006not yet assessed
-
[Helicobacter pylori can in rare cases be the cause of iron and vitamin B 12 deficiency. No increased risk of iron and vitamin B 12 deficiency due to proton pump inhibitors]. ↗PubMed · 2004 · PMID 15232839not yet assessed
-
The Crystal Structures of Kbm1 and Kbm8 Reveal that Subtle Changes in the Peptide Environment Impact Thermostability and Alloreactivity ↗Immunity · 2001 · PMID 11290333not yet assessed
-
MHC CLASS I NATURAL MUTANT H-2KBM1 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN ↗Worldwide Protein Data Bank · 2000not yet assessed
-
MHC CLASS I NATURAL MUTANT H-2KBM1 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN ↗Worldwide Protein Data Bank · 2000not yet assessed
-
MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN ↗Worldwide Protein Data Bank · 2000not yet assessed
-
MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN ↗Worldwide Protein Data Bank · 2000not yet assessed
-
Roles for glycosylation of cell surface receptors involved in cellular immune recognition ↗Journal of Molecular Biology · 1999 · PMID 10529350not yet assessed
-
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s diseaseRePEc: Research Papers in Economics ·not yet assessed
Full bibliography from OpenAlex; reproducibility verdicts matched by PMID.
Author attribution follows OpenAlex disambiguation, which is imperfect — a researcher's papers can be split across profiles or mixed with a namesake.
Merged across profiles sharing this ORCID where present. See every “Mattsson N” paper on PubMed ↗